Big Pharma Split Corp Class A (PRM) - Total Liabilities
Based on the latest financial reports, Big Pharma Split Corp Class A (PRM) has total liabilities worth CA$13.57 Million CAD (≈ $9.82 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how much of Big Pharma Split Corp Class A's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Big Pharma Split Corp Class A - Total Liabilities Trend (2017–2025)
This chart illustrates how Big Pharma Split Corp Class A's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Big Pharma Split Corp Class A balance sheet assets.
Big Pharma Split Corp Class A Competitors by Total Liabilities
The table below lists competitors of Big Pharma Split Corp Class A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Argenica Therapeutics Ltd
AU:AGN
|
Australia | AU$1.76 Million |
|
e-future.Co.Ltd
KQ:134060
|
Korea | ₩4.56 Billion |
|
DeepMarkit Corp.
NASDAQ:MKTSF
|
USA | $778.36K |
|
Nepa AB
ST:NEPA
|
Sweden | Skr70.20 Million |
|
Neungyule Education Inc
KQ:053290
|
Korea | ₩19.28 Billion |
|
CMX GOLD+SILVER CORP.
F:6GS
|
Germany | €733.54K |
|
FIPP S.A.
PA:FIPP
|
France | €28.40 Million |
|
Intersport Polska S.A.
WAR:IPO
|
Poland | zł210.92 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Big Pharma Split Corp Class A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Big Pharma Split Corp Class A balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.33 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.74 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Big Pharma Split Corp Class A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Big Pharma Split Corp Class A (2017–2025)
The table below shows the annual total liabilities of Big Pharma Split Corp Class A from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CA$13.57 Million ≈ $9.82 Million |
+7.56% |
| 2024-12-31 | CA$12.62 Million ≈ $9.13 Million |
+18.12% |
| 2023-12-31 | CA$10.68 Million ≈ $7.73 Million |
-44.83% |
| 2022-12-31 | CA$19.37 Million ≈ $14.01 Million |
+25.66% |
| 2021-12-31 | CA$15.41 Million ≈ $11.15 Million |
+58.10% |
| 2020-12-31 | CA$9.75 Million ≈ $7.05 Million |
-10.30% |
| 2019-12-31 | CA$10.87 Million ≈ $7.86 Million |
-26.51% |
| 2018-12-31 | CA$14.79 Million ≈ $10.70 Million |
+7.08% |
| 2017-12-31 | CA$13.81 Million ≈ $9.99 Million |
-- |
About Big Pharma Split Corp Class A
Big Pharma Split Corp is a closed ended equity mutual fund launched and managed by Harvest Portfolios Group Inc. It invests in the public equity markets across United States. The fund primarily invests in the Pharmaceutical sector. Big Pharma Split Corp was formed on September 15, 2017 and is domiciled in Canada.